Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07351019

Colonoscopy Bowel Prep Comparison Among Diabetic Patients

The goal of this clinical trial is to learn if the Golytely or SUPREP bowel preparation works more effectively in bowel cleansing for colorectal cancer screening with colonoscopy in patients with diabetes. The main questions this study aims to answer are:

1. Is there a significant difference in bowel prep cleanse between Golytely and SUPREP in patients with diabetes based on the Boston Bowel Prep Score (BBPS) as assessed by blinded, skilled endoscopists? 2. Is there a significant difference in patients' tolerance between the bowel preparations as assessed by the validated Mayo Bowel Prep Tolerability Form (MBPTF)?

Participants will:

* Be randomized to take either Golytely or SUPREP bowel preparation prior to their colonoscopy * Complete the MBPTF on the procedure date prior to the scheduled colonoscopy * Undergo a standardized screening colonoscopy during which time a blinded endoscopist will document the participant's BBPS

The research team hypothesizes that SUPREP will have a significant difference in tolerability (based on MBPTF), while exhibiting no difference in bowel cleanse (based on BBPS) in the diabetic patient population.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Colon Cancer Screening

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Dwight D. Eisenhower Army Medical Center

Fort Gordon, Georgia, 30905, United States

Location status: Recruiting

Location contact

Darrell F Barker MD, FACG, MD

CONTACT

[email protected]

706-836-9829

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participants having provided informed consent with signature on informed consent form: the informed consent process should be complete with full discussion of all requirements and possible risks.
  • Diabetic volunteer (defined per current ACP guidelines, and any type of DM)
  • Aged 18+ years, inclusive
  • Average screening risk, polyp surveillance, and family history of cancer

Exclusion criteria

  • Unable to provide informed consent to participate in the study Such as a mental condition rendering the participant unable to understand the nature, scope, and possible consequences of the study
  • Clinically relevant cardiovascular, hepatic, neurological, endocrine, or other major systemic disease making implementation of the protocol or interpretation of the study results difficult or that would put the participant at risk by participating in the study
  • Persistent significant or severe infection, either acute or chronic
  • Prior use of any investigational drug in the preceding 6 months
  • Liver function impairment or persisting elevations (confirmed by retest) of alanine aminotransferase (ALT), aspartate aminotransferase (AST), or direct bilirubin greater than 2x the upper limit of normal range (ULN).
  • Pregnant or breast-feeding women or those who plan to become pregnant during the study
  • Participants with significantly impaired bone marrow function or significant anemia, leukopenia, or thrombocytopenia (confirmed by retest):
  • Hematocrit < 35% and/or
  • Absolute white blood cell count < 3000 cells/mm3 ( L) and/or
  • Platelet count < 150 000 cells/mm3 ( L) and/or- Absolute neutrophil = 1500 cells/mm3 ( L)
  • History of colorectal cancer
  • Inflammatory Bowel Disease
  • Past surgical history of colon resection
  • Prior history of colorectal surgery
  • Family history of hereditary polyposis and cancer disorders to include but not limited to FAP (Familial Adenomatous Polyposis), Gardner Syndrome, Turcot Syndrome, Lynch Syndrome, Cowden Syndrome, and Peutz-Jeghers Syndrome
  • Symptomatic patients (bleeding, diarrhea, constipation, abdominal pain)

Treatment and study plan

Golytely

Drug

Bowel cleanliness and patient tolerability

SUPRPEP

Drug

Bowel cleanliness and patient tolerability

Primary outcomes

  1. Bowel cleanliness using the Boston Bowel Prep Score (BBPS)

    Time frame: Procedural (during the participant's screening colonoscopy)

    The BBPS uses a score from 0-9 which helps quantify bowel cleanliness after bowel prep prior to colonoscopy. A higher score indicates better visualization of the colon mucosa. This will be assessed by blinded, skilled endoscopists.

  2. Use of the Mayo Bowel Prep Tolerability Score (MTS)

    Time frame: Pre-procedural (prior to the participant's screening colonoscopy)

    The questionnaire is a validated scoring system used to assess the tolerability (ex. symptoms) and experience (ex. likelihood of using the bowel prep again) among diabetic patients undergoing the study.

Study contacts

Contact information is provided by the study sponsor or research team.

Darrell F Barker MD, FACG, MD

CONTACT

[email protected]

706-836-9829

Sponsors and collaborators

Lead sponsor

Eisenhower Army Medical Center

Fed

Registry information

Official study title

Colonoscopy Bowel Prep Comparison Among Diabetic Patients: Golytely v. SUPREP

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Jan 20, 2026
Registry last updated
Jan 20, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.